Latest News and Press Releases

Toronto, Canada, March 03, 2021 (GLOBE NEWSWIRE) -- It’s a new era of investing. Platforms like Twitter, Reddit, StockTwits and dozens of others, have become online destinations for a wide variety...

New York City, USA, March 03, 2021 (GLOBE NEWSWIRE) -- It’s a new era of investing. Platforms like Twitter, Reddit, StockTwits and dozens of others, have become online destinations for a wide...

Preliminary data on AUTO3 in DLBCL demonstrate safety and feasibilty of CD19 and CD22 dual targeting CAR T 90% complete response and 100% overall survival at 12 months in CAR T naive pediatric ALL...

LONDON, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, and Noile-Immune...

Findings from Phase I CARPALL Trial Demonstrate that Autolus’ Novel CAR T Therapy, AUTO1, Induces Enhanced Anti-tumor Response Without Severe Cytokine Release Syndrome 86% molecular complete...

LONDON, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...

Pittsburgh, PA, May 30, 2019 (GLOBE NEWSWIRE) -- In early 2019, the Pittsburgh Cultural Trust opened the doors to Liberty Magic, an immersive, speakeasy theater space dedicated to the art of...

LONDON, May 14, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...

LONDON, May 07, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...

Atlanta, Georgia, May 06, 2019 (GLOBE NEWSWIRE) -- For  the last 28 years, Dr. James Chappuis an Atlanta based  Spinal specialist has been a visionary in his field, Dr. James L. Chappuis FACS sits...